Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Sharp Debridement vs Santyl for Diabetic Foot Wounds
NCT01056198Phase 4Completed
- Sponsor
- Healthpoint Biotherapeutics
- Start
- Feb 2010
- Primary completion
- Aug 2011
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of collagenase clostridium histolyticum in diabetic foot ulcer (DFU) (2 arms), sponsored by Healthpoint Biotherapeutics. Primary endpoint: Bates-Jensen Wound Assessment Score - Modified at 28 days. Started Feb 2010; status: completed.
02
Drugs
collagenase clostridium histolyticum
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT01056198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01056198.